乾眼症市場規模、佔有率和成長分析（按產品類型、配方類型、分銷管道和地區）- 2025-2032 年產業預測

預計乾眼症市場規模在 2023 年將達到 56 億美元，並從 2024 年的 60.5 億美元成長到 2032 年的 112.9 億美元，預測期內（2025-2032 年）的複合年成長率為 8.1%。

全球乾眼症 (DED) 市場的發展受到老年族群，尤其是女性族群中乾眼症發病率不斷上升的推動。瘢痕性角膜炎和淚液功能障礙綜合症等症狀凸顯了這種眼表疾病的重要性，它影響著相當一部分老年人口。世界衛生組織 (WHO) 預測，2015 年至 2050 年期間，60 歲或以上人口的比例將幾乎加倍，從 12% 增至 22%，其中 80%居住在中低收入國家，對有效的乾眼症治療的需求將日益成長。在這個快速成長的市場中，加強臨床試驗和研究對於提高藥物採用率至關重要，特別是隨著老年人群越來越容易患上眼部疾病。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

乾眼症市場規模（依產品類型）：及複合年成長率（2025-2032）

• 市場概況
• Cyclosporine
• 皮質類固醇
• 利菲特羅
• 眼部潤滑劑
• 淚點塞
• 其他

乾眼症市場規模（按配方類型和複合年成長率） (2025-2032)

• 市場概況
• 液體
• 凝膠
• 軟膏
• 其他

乾眼症市場規模（依通路）：及複合年成長率（2025-2032）

• 市場概況
• 醫院藥房
• 零售藥局
• 超級市場/大賣場
• 其他商店
• 網路藥局

乾眼症市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Novartis（Switzerland）
• Allergan（Ireland）
• AbbVie（US）
• Johnson & Johnson（US）
• Bausch+Lomb（Canada）
• Rohto Pharmaceutical Co., Ltd.（Japan）
• Oculis（Switzerland）
• Visus Therapeutics（US）
• Kala Pharmaceuticals（US）
• Sun Pharmaceutical Industries Ltd.（India）
• Prestige Consumer Healthcare（US）
• Similasan Corporation（Switzerland）
• Scope Ophthalmics（UK）
• Thea Pharmaceuticals（France）
• Ursapharm Arzneimittel GmbH（Germany）
• EyeGate Pharmaceuticals, Inc.（US）
• Aldeyra Therapeutics（US）
• QuidelOrtho Corporation（US）

結論和建議

Dry Eye Disease Market size was valued at USD 5.6 billion in 2023 and is poised to grow from USD 6.05 billion in 2024 to USD 11.29 billion by 2032, growing at a CAGR of 8.1% during the forecast period (2025-2032).

The global dry eye disease (DED) market is poised for growth, driven by an increasing prevalence of the condition among older adults, particularly women. Conditions like keratitis sicca and dysfunctional tear syndrome underline the significance of this ocular surface disease, which affects a substantial segment of the aging population. With the World Health Organization projecting that individuals aged 60 and above will nearly double from 12% to 22% between 2015 and 2050, and with a striking 80% of this demographic residing in low- and middle-income countries, the demand for effective dry eye treatments is set to rise. Enhanced clinical trials and research are essential to boost drug penetration in this burgeoning market, particularly as the elderly population becomes more vulnerable to eye disorders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Dry Eye Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Dry Eye Disease Market Segments Analysis

Global Dry Eye Disease Market is segmented by Product Type, Formulation Type, Distribution Channel: and region. Based on Product Type, the market is segmented into Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Others. Based on Formulation Type, the market is segmented into Liquid, Gel, Ointment and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Supermarket/Hypermarket, Other Stores and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Dry Eye Disease Market

The dry eye disease market, encompassing conditions like keratoconjunctivitis sicca (KCS), serves an extensive population, with around 360 million affected globally. This prevalent ocular disorder manifests through symptoms of dryness, irritation, redness, fatigue, and blurred vision. The incidence is not limited to age, as it is increasingly observed in both younger and older demographics, largely attributed to heightened screen exposure, poor dietary habits, growing contact lens usage, and more frequent LASIK surgeries. As individuals age, the lachrymal glands' tear production diminishes, leading to dry eye complaints. Hence, the escalating prevalence of dry eye disease, particularly among aging populations, significantly propels the demand for dry eye treatments in the market.

Restraints in the Dry Eye Disease Market

The Dry Eye Disease market faces significant restraints due to a lack of public awareness regarding eye health. Many individuals do not recognize the importance of seeking treatment for common dry eye symptoms, which are often misconstrued and can be effectively managed with accurate diagnosis and appropriate medications. Typically, patients only consult ophthalmologists when experiencing severe discomfort, leading to the underdiagnosis of symptoms like redness and burning. This lack of recognition limits the pool of individuals who could benefit from prescription treatments. A UK survey revealed that one in four adults neglects biannual eye examinations as recommended, indicating a pervasive ignorance around eye health, particularly among children.

Market Trends of the Dry Eye Disease Market

The dry eye disease market is experiencing a notable upward trend characterized by heightened investment in research and development, culminating in successful clinical trials and a surge in new product approvals. Pharmaceutical companies like Aldeyra Therapeutics, Inc. are leading the charge with promising candidates like Reproxalap, currently in Phase III trials, setting a precedent for innovation. This influx of clinical activity not only fosters competitive differentiation but also enhances the treatment landscape, thereby significantly boosting revenue potential. Such strategic initiatives reflect a commitment to addressing unmet needs and solidifying market presence, positioning the dry eye disease market for robust growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Dry Eye Disease Market Size by Product Type: & CAGR (2025-2032)

• Market Overview
• Cyclosporine
• Corticosteroids
• Lifitegrast
• Ocular Lubricant
• Punctal Plugs
• Others

Global Dry Eye Disease Market Size by Formulation Type: & CAGR (2025-2032)

• Market Overview
• Liquid
• Gel
• Ointment
• Others

Global Dry Eye Disease Market Size by Distribution Channel: & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Supermarket/Hypermarket
• Other Stores
• Online Pharmacies

Global Dry Eye Disease Market Size & CAGR (2025-2032)

• North America (Product Type:, Formulation Type:, Distribution Channel:)
  • US
  • Canada
• Europe (Product Type:, Formulation Type:, Distribution Channel:)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type:, Formulation Type:, Distribution Channel:)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type:, Formulation Type:, Distribution Channel:)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type:, Formulation Type:, Distribution Channel:)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch + Lomb (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rohto Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oculis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Visus Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kala Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prestige Consumer Healthcare (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Similasan Corporation (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Scope Ophthalmics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thea Pharmaceuticals (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ursapharm Arzneimittel GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyeGate Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aldeyra Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QuidelOrtho Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations